NRx Pharmaceuticals, Inc.
NRXP
$3.87
-$0.46-10.62%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -1.78% | -13.91% | -86.75% | -36.16% | 5.96% |
| Total Depreciation and Amortization | 6,060.00% | 2,780.00% | 800.00% | -20.00% | 0.00% |
| Total Amortization of Deferred Charges | -100.00% | -60.94% | 39.16% | -- | -- |
| Total Other Non-Cash Items | -19.60% | 51.95% | 7,562.96% | 838.86% | 554.31% |
| Change in Net Operating Assets | -42.08% | -73.37% | -100.45% | -106.52% | -39.40% |
| Cash from Operations | -42.90% | -32.67% | -6.53% | 14.85% | 45.70% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -256,200.00% | -- | -- |
| Total Debt Issued | -96.79% | -96.79% | 40.90% | 4,696.82% | 650.69% |
| Total Debt Repaid | 96.62% | 93.61% | 31.35% | -11.67% | -8.89% |
| Issuance of Common Stock | -46.51% | 144.76% | 144.76% | 48.88% | 42.93% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 374.38% | 197.36% | 285.70% | -- | -- |
| Cash from Financing | 30.26% | 210.97% | 360.35% | 1,306.31% | 262.26% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -72.45% | 301.59% | 176.32% | 107.74% | 127.85% |